July 29, 2020 Clinical Trials

Youth ages 12-18 years old may qualify for this new Chronic Plaque Psoriasis study.

Study focuses on how a drug called Risankizumab may help children with moderate to severe psoriasis. Psoriasis is a condition in which skin cells build up and form red, itchy, scaly patches. Risankizumab is approved for use in adults however, it has been not been approved for children in the United States and other countries, and we want to learn more about how it works. This is called a “research study.” This is the first study where the study drug will be tested in children.

If you decide to be in the research study, you will be asked to take part in this study for about 65 weeks and this may include 9 study visits and 1 follow-up phone call. You will receive a risankizumab injection every 12 weeks after the week 4 visit.

You will need your parent’s approval to participate in this study if you are younger than 18.

Call 817-795-7546 or email if you think you would like to participate in this study.


July 29, 2020 Clinical Trials

Open to adolescents only. Patient must have moderate Atopic Dermatitis to be eligible to participate. Must meet the following criteria to participate:

Aged 12-18 years old

Active moderate to severe AD on body surface area (BSA) of ≥10%, and pruritus
Candidate for systemic therapy or have recently required systemic therapy for AD
No prior exposure to any JAK inhibitor
Able and willing to discontinue current AD treatments prior to the study
No requirement of prohibited medications during the study
No other active skin diseases or skin infections requiring systemic treatment that would interfere with appropriate assessment of AD lesions
Female subjects cannot be pregnant, breastfeeding, or considering pregnancy during the study.

The study is expected to last for just under 3 years.

Call 817-795-7546 or email if you think you would like to participate in this study.

Copyright © 2020 . All rights reserved. Website Designed by Gott Marketing